With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

“Gilead’s third quarter results are the strongest of the year to date,” said Daniel O’Day, Chairman and CEO, Gilead ...

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

Rowe Price was the bigger shareholder, with a 10.1% stake, followed by Novo Holdings—the controlling shareholder of Novo ...

Oral phenylephrine was shown to be ineffective for treating nasal congestion over a year go. This week, the FDA took the ...